|Articles|July 1, 2004
Consider the complete picture of a therapy's efficacy
I am writing to add clarification to an article about dry eye that underreports the clinical efficacy and symptom improvement period for cyclosporine (CsA) ophthalmic emulsion 0.05% (Restasis, Allergan) ("Dry eye: what's in the pipeline?" by Joseph Mussoline, MD, Ophthalmology Times, March 15, 2004, Pages 18 to 19).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Advancements in laser refractive surgery
2
From then to next: Five decades of transformation in ophthalmology
3
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
4
Kodiak Sciences releases follow-up, 20-week data from APEX study
5














































.png)


